吉祥坊登录

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) has recently received registration approval from the Health Sciences Authority (HSA) of Singapore for its HerculesTM Thoracic Stent Graft with Low Profile Delivery System covered stent (hereafter referred to as "Hercules TM -LP Stent Graft"). This is the first product of MicroPort Endovastec to have been approved for market in Singapore.

The HerculesTM -LP Stent Graft is mainly used for the endovascular treatment of thoracic aortic aneurysms or Stanford type B aortic dissection. Its delivery system adopts a Low-Profile design with 18F delivery sheath diameter, which can adapt to narrower and more tortuous-access arteries. The delivery system is also equipped with inner sheath to protect the stent graft when crossing the aortic arch. This product uses a tip-capture mechanism, which makes the release process more precise and controllable. In addition, the stent's various taper designs can better conform to the anatomy of the thoracic aortic dissection.

The Hercules TM -LP Stent Graft received CE certification from the EU in 2020 and has now entered clinical use in 16 overseas countries worldwide, and is successfully treating thousands of patients with aortic diseases. In recent years, the demand for medical devices in Singapore has grown rapidly. The approval of the Hercules TM -LP Stent Graft registration in Singapore will lay the foundation for the company to further expand into the Southeast Asian market and open new possibilities. MicroPort Endovastec will continue to promote its high-quality innovative products to more countries around the world in order to benefit more patients.